COVID-19 is an infectious disease caused by the new coronavirus, SARS-CoV2, with a heterogeneous clinical course, ranging from asymptomatic patients to critically ill patients with multiple organ dysfunction. It is well known that the severity of the disease is secondary to a dysregulated inflammatory response known as a cytokine storm. Hemoabsorptive therapies, such as the Cytosorb device, could be a useful treatment alternative in severely ill patients with cytokine storm, due to its beneficial effect by purifying inflammatory mediators in septic patients, postoperative of cardiovascular surgery, with pancreatitis, and even poisoned.